Repare Therapeutics Inc.
USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS
Last updated:
Abstract:
Disclosed are methods of treating a cancer in a subject using an ATR inhibitor and PARP inhibitor. wherein the cancer has been previously identified as a cancer having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or as an ALT+ cancer. Also disclosed are methods of inducing cell death in an aberrant cancer cell having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or an ALT+ cancer cell, by contacting the cell with an effective amount of an ATR inhibitor and PARP inhibitor.
Status:
Application
Type:
Utility
Filling date:
11 Dec 2020
Issue date:
17 Jun 2021